← Association for Accessible Medicines
FDANonrulemakingFDA-2024-D-4624

Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics; Draft Guidance for Industry; Availability

RIN
—
Last modified
Jan 8, 2026
Comment window
closed 560d ago
Association for Accessible Medicines filings
1

Activity

Association for Accessible Medicines filed 1 comment on this docket between Jan 14, 2025 and Jan 14, 2025. 0 other organizations filed here. The comment window closed 560d ago.

What Association for Accessible Medicines filed (1)

Jan 14, 2025· Comment from Association for Accessible Medicines (AAM)· FDA-2024-D-4624-0006

FDA, Please find attached comments from the Association for Accessible Medicines (AAM) regarding Docket No. FDA-2024-D-4624 "Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics; Draft Guidance for Industry" Thanks, Scott Kuzner, Ph.D., Senior Director, Sciences and Regulatory Affairs, AAM

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (0)

See everyone who commented →